Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +35

Becton Dickinson (BDX) Surpasses Q4 Earnings and Revenue Estimates

Earnings report AI-generated analysis

πŸ“ˆ Becton Dickinson reported Q4 earnings of $4.15 per share, beating the consensus estimate of $4.06 by 2.22%.

πŸ’° Quarterly revenue reached $5.27 billion, surpassing analyst expectations by 2.96% despite being lower than the prior year's $5.89 billion.

πŸ“Š The company has topped consensus EPS estimates for four consecutive quarters over the last twelve months.

πŸ“ˆ BDX shares have risen approximately 7.8% year-to-date, though they have underperformed the S&P 500's 12.3% gain.

πŸ”­ The stock holds a Zacks Rank #2 (Buy) rating due to favorable earnings estimate revisions prior to the report release.

πŸ“… Analysts project Q1 consensus EPS of $2.69 on revenues of $4.77 billion for the upcoming quarter.

πŸ₯ Becton Dickinson operates in the Medical - Dental Supplies industry, which is currently ranked in the top 30% of all industries.

Bullish Signals
  • The company beat Q4 earnings estimates by $0.09 per share, marking the fourth consecutive quarter of surpassing consensus EPS expectations.
  • Revenue of $5.27 billion exceeded analyst forecasts by 2.96%, demonstrating consistent ability to meet or exceed market predictions.
  • The stock maintains a Zacks Rank #2 (Buy) rating, indicating a high probability of outperforming the market based on favorable earnings estimate trends.
Risk Factors
  • Quarterly revenue of $5.27 billion was significantly lower than the year-ago figure of $5.89 billion, indicating a potential decline in top-line growth.
  • The stock has underperformed the broader S&P 500 index by approximately 4.5 percentage points since the beginning of the year.
Full Analysis
Becton Dickinson and Company (BDX) reported fourth-quarter earnings of $4.15 per share, surpassing the Zacks Consensus Estimate of $4.06. This result represents a 2.22% positive surprise compared to analyst expectations, continuing a streak where the company has beaten EPS estimates for four consecutive quarters. Revenue for the quarter ended September 2026 reached $5.27 billion, exceeding consensus estimates by 2.96%, although this figure is lower than the year-ago period of $5.89 billion. The stock has gained approximately 7.8% year-to-date, trailing the S&P 500's 12.3% gain. Despite the underperformance relative to the broader market so far this year, BDX maintains a Zacks Rank #2 (Buy) rating based on favorable earnings estimate revisions ahead of the report. The company operates within the Medical - Dental Supplies industry, which currently ranks in the top 30% among all tracked industries. Looking forward, the consensus EPS estimate for the coming quarter is set at $2.69 with projected revenues of $4.77 billion. For the current fiscal year, analysts expect earnings of $13.24 on revenues totaling $19.91 billion. The sustainability of BDX's stock price movement will largely depend on management's commentary during the upcoming earnings call and subsequent trends in earnings estimate revisions.